Retro and prospective Evaluation of the results of biopsies and ablations of renal massens at the University Medical Center Goettingen

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00028690

Enrollment

Registered

2022-05-23

Start date

2021-04-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C64

Interventions

Group 1: Biopsy of renal masses Group 2: Ablation of renal masses

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients >/=18 years of age with renal tumor biopsy and/or ablation

Exclusion criteria

Exclusion criteria: Patients <18 years and such that are not able to understand the study or sign informed consent

Design outcomes

Primary

Measure	Time frame
Primary endpoint for the biopsies is the diagnostic accuracy evaluated by the rate of diagnostic biopsies. Non-diagnostic biopsies are biopsies with too few, fibrotic material or biopsy cores outside the tumor lesion. For the ablation techniques we evaluate rates of local recurrence (therapeutic efficiency).	—

Secondary

Measure	Time frame
For both interventions we will evaluate complication rates after Clavien-Dindo. For biopsies the further therapeutic measures will be documented (resection, ablation, surveillance). For the ablations rates of metastases, survival (overall and cancer specific) and long term complications will be documented.	—

Countries

Germany

Contacts

Public ContactAnnemarie Uhlig

Universitätsmedizin Göttingen

annemarie.uhlig@med.uni-goettingen.de05513965891

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026